PRX302 (topsalysin), is a modified recombinant protein that has been engineered to be selectively activated by an enzyme in the prostate, leading to localized cell death and tissue disruption without damaging neighboring tissue and nerves. PRX302 is currently being developed as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), and as a treatment for localized low to intermediate risk prostate cancer.
A Highly Targeted Treatment
PRX302 binds to the GPI-anchored receptors on the cell surface of prostate cells. Once activated by PSA, PRX302 combines with other activated PRX302 molecules, forming stable transmembrane pores that induce cell death. The prostate specific activation of PRX302 by enzymatically active PSA thus limits exposure of non-prostate tissues to the drug’s activity, contributing to the safety of the therapy.
The mechanism of action is shown in the figure below.